Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039778 · ClinicalTrials.gov registry record · NA
Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma
A NA study, sponsored by Beth Israel Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02039778 is a NA study that was terminated before completion, run by Beth Israel Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT02039778, a NA study, was terminated before completion, sponsored by Beth Israel Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
There are preliminary studies that suggest that radiation therapy to areas of the brain containing cancer stem cells (in addition to the area where the tumor was surgically treated) may help patients with high-grade brain tumors live longer. The purpose of this study is to determine whether the addition of stem-cell radiation therapy to the standard chemoradiation will further improve the outcome. The investigators will collect information about the patient's clinical status, disease control, neurocognitive effects, and quality of life during follow-up in our department. The purpose of the study is to improve the overall survival patients with newly diagnosed malignant brain tumors treated with stem cell radiation therapy and chemotherapy. The investigators will also measure how patients treated with this novel method of radiation therapy do over time in terms of disease control, potential neurocognitive side effects, overall function, and quality of life.
Interventions
- RADIATION Stem Cell Radiotherapy (ScRT) and Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039778
The ClinicalTrials.gov registry entry for NCT02039778 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stem Cell Radiotherapy (ScRT) and Temozolomide is the first listed.
NCT02039778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039778 about?
NCT02039778 is a clinical study titled "Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma". There are preliminary studies that suggest that radiation therapy to areas of the brain containing cancer stem cells (in addition to the area where the tumor was surgically treated) may help patients with high-grade brain tumors live longer. The purpose of this study is to determine whether the addi...
What is the current status of trial NCT02039778?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2013-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02039778?
The interventions under investigation include: Stem Cell Radiotherapy (ScRT) and Temozolomide (RADIATION).
Who is sponsoring clinical trial NCT02039778?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.